{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:59:57Z","timestamp":1781243997728,"version":"3.54.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Despite the decline of the global peak of COVID-19, SARS-CoV-2 continues to circulate, evolve, and undergo immune escape, posing persistent threats, particularly to older adults, individuals with comorbidities, and immunocompromised populations. Although existing vaccination strategies have substantially reduced the risks of severe disease, hospitalization, and death, their ability to block infection and transmission remains limited, and protection wanes over time. Current heterologous booster strategies still rely largely on combinations of different parenteral vaccine platforms. Although these regimens can enhance systemic humoral and cellular immunity, they are insufficient to robustly induce upper respiratory mucosal immunity, thereby limiting their role in early infection control and interruption of transmission. Because respiratory mucosal vaccines target the natural entry site of SARS-CoV-2, they have the potential to induce secretory IgA, tissue-resident memory immune cells, and local immune memory, offering distinct advantages in compensating for the shortcomings of conventional heterologous boosting. Combining heterologous boosting with respiratory mucosal delivery may further enhance the control of viral infection, early replication, and subsequent transmission while preserving systemic immunity, thereby providing more comprehensive immune protection for high-risk populations. However, this strategy still faces challenges related to mucosal barriers, delivery efficiency, adjuvant safety, manufacturing scale-up, and incomplete clinical evaluation frameworks. Future high-quality studies focusing on high-risk populations are needed to clarify its value in preventing infection, protecting against severe disease, and providing long-term protection.<\/jats:p>","DOI":"10.3389\/fpubh.2026.1849650","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:47:50Z","timestamp":1781243270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing COVID-19 vaccination strategies for high-risk populations: potential and challenges of combining heterologous boosting with respiratory mucosal delivery"],"prefix":"10.3389","volume":"14","author":[{"given":"Ruixia","family":"Miao","sequence":"first","affiliation":[{"name":"School of Public Health, Gansu University of Chinese Medicine","place":["LanZhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Public Health, Gansu University of Chinese Medicine","place":["LanZhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Public Health, Gansu University of Chinese Medicine","place":["LanZhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Public Health, Gansu University of Chinese Medicine","place":["LanZhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Lei","sequence":"additional","affiliation":[{"name":"School of Public Health, Gansu University of Chinese Medicine","place":["LanZhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Gansu Provincial Hospital","place":["LanZhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Public Health, Gansu University of Chinese Medicine","place":["LanZhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Gansu Provincial Hospital","place":["LanZhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-024-44973-1","article-title":"Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population","volume":"15","author":"Wei","year":"2024","journal-title":"Nat Commun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.15585\/mmwr.mm7312a5","article-title":"Interim effectiveness of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccines against COVID-19-associated hospitalization among adults aged \u226518 years with immunocompromising conditions-VISION network, September 2023-February 2024","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-024-01846-9","article-title":"Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12985-023-02056-5","article-title":"Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort","volume":"20","author":"Huang","year":"2023","journal-title":"Virol J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"106177","DOI":"10.1016\/j.jinf.2024.106177","article-title":"Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study","volume":"89","author":"Kirsebom","year":"2024","journal-title":"J Infect."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1016\/j.vaccine.2023.10.011","article-title":"Effectiveness of homologous\/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries","volume":"41","author":"Riefolo","year":"2023","journal-title":"Vaccine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"25151355241285375","DOI":"10.1177\/25151355241285375","article-title":"Relative effectiveness of COVID-19 vaccine booster doses in people aged 65 and older-a retrospective cohort study in T\u00fcrkiye","volume":"12","author":"Sezerol","year":"2024","journal-title":"Ther Adv Vaccines Immunother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s43856-023-00277-x","article-title":"Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity","volume":"3","author":"Dietz","year":"2023","journal-title":"Commun Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cmi.2022.03.003","article-title":"Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study","volume":"28","author":"S\u00f8gaard","year":"2022","journal-title":"Clin Microbiol Infect."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1016\/j.vaccine.2023.02.038","article-title":"Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities","volume":"41","author":"Smits","year":"2023","journal-title":"Vaccine."},{"key":"B13","doi-asserted-by":"publisher","first-page":"eadp8920","DOI":"10.1126\/scitranslmed.adp8920","article-title":"SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity","volume":"16","author":"Lasrado","year":"2024","journal-title":"Sci Transl Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/infdis\/jiab592","article-title":"Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults","volume":"225","author":"Brockman","year":"2022","journal-title":"J Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamainternmed.2021.7372","article-title":"Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs. heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial","volume":"182","author":"Reindl-Schwaighofer","year":"2022","journal-title":"JAMA Intern Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12916-024-03471-3","article-title":"heterologous vs. homologous COVID-19 booster vaccinations for adults: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials","volume":"22","author":"Asante","year":"2024","journal-title":"BMC Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e70056","DOI":"10.1002\/mco2.70056","article-title":"Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications","volume":"6","author":"Zhou","year":"2020","journal-title":"MedComm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1056\/NEJMoa2116747","article-title":"Immunogenicity and reactogenicity of vaccine boosters after Ad26. COV2S Priming","volume":"386","author":"Sablerolles","year":"2022","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1038\/s41467-022-33169-0","article-title":"Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil","volume":"13","author":"Ranzani","year":"2022","journal-title":"Nat Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41541-025-01280-0","article-title":"Advances and prospects of respiratory mucosal vaccines: mechanisms, technologies, and clinical applications","volume":"10","author":"Li","year":"2025","journal-title":"NPJ Vaccines."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1330864","DOI":"10.3389\/fimmu.2024.1330864","article-title":"Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva","volume":"15","author":"Winklmeier","year":"2024","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41590-024-01951-5","article-title":"Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB","volume":"25","author":"Gagne","year":"2024"},{"key":"B25","doi-asserted-by":"publisher","first-page":"eabo2523","DOI":"10.1126\/science.abo2523","article-title":"Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses","volume":"378","author":"Mao","year":"2022","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.scib.2022.05.018","article-title":"A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2","volume":"67","author":"Chen","year":"2022","journal-title":"Sci Bull."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1080\/22221751.2022.2119169","article-title":"Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates","volume":"11","author":"Tukhvatulin","year":"2022","journal-title":"Emerg Microbes Infect."},{"key":"B28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/vaccines12050491","article-title":"Induction of superior systemic and mucosal protective immunity to SARS-CoV-2 by Nasal administration of a VSV-\u0394G-Spike vaccine","volume":"12","author":"Yahalom-Ronen","year":"2024","journal-title":"Vaccines"},{"key":"B29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-023-06951-3","article-title":"Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques","volume":"626","author":"McMahan","year":"2024","journal-title":"Nature."},{"key":"B30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S1473-3099(23)00350-X","article-title":"Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial","volume":"23","author":"Li","year":"2023","journal-title":"Lancet Infect Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1016\/j.ymthe.2024.10.016","article-title":"Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime\/intranasal protein boost vaccination with a combination adjuvant","volume":"32","author":"Laghlali","year":"2024","journal-title":"Mol Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S2213-2600(23)00349-1","article-title":"Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Zhu","year":"2023","journal-title":"Lancet Respir Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0140-6736(24)01136-X","volume":"404","author":"Greenhalgh","year":"2024","journal-title":"Long COVID: a Clinical Update"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.vaccine.2019.11.047","article-title":"A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(\u03b1K): a phase II study","volume":"38","author":"Pan","year":"2020","journal-title":"Vaccine."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2022.05.002","volume":"150","author":"Baker","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1016\/j.apsb.2022.07.002","article-title":"Mucosal vaccine delivery: a focus on the breakthrough of specific barriers","volume":"12","author":"Huang","year":"2022","journal-title":"Acta Pharm Sin B."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0139368","DOI":"10.1371\/journal.pone.0139368","article-title":"Nasal administration of cholera toxin as a mucosal adjuvant Damages the olfactory system in Mice","volume":"10","author":"Fukuyama","year":"2015","journal-title":"PLoS ONE."},{"key":"B39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1016\/j.apsb.2024.08.026","article-title":"Respiratory delivered vaccines: current status and perspectives in rational formulation design","volume":"14","author":"Wu","year":"2024","journal-title":"Acta Pharm Sin B."},{"key":"B41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41541-022-00447-3","article-title":"Pandemic-response adenoviral vector and RNA vaccine manufacturing","volume":"7","author":"Kis","year":"2022","journal-title":"NPJ Vaccines."},{"key":"B42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/82_2011_167","article-title":"Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery","volume":"354","author":"Wang","year":"2012","journal-title":"Curr Top Microbiol Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1080\/21645515.2017.1356952","article-title":"Developments in the formulation and delivery of spray dried vaccines","volume":"13","author":"Kanojia","year":"2017","journal-title":"Hum Vaccin Immunother."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1849650\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:47:53Z","timestamp":1781243273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1849650\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":43,"alternative-id":["10.3389\/fpubh.2026.1849650"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1849650","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1849650"}}